Aditi Narsale1, Joanna D Davies2. 1. San Diego Biomedical Research Institute, 10865 Road to the Cure, Suite 100, San Diego, CA, 92121, USA. 2. San Diego Biomedical Research Institute, 10865 Road to the Cure, Suite 100, San Diego, CA, 92121, USA. jdavies@sdbri.org.
Abstract
PURPOSE OF REVIEW: Therapies that target beta-cell antigen-specific T cells subsets have not been as successful in patients with type 1 diabetes as in mice. This might be explained by complexities in the repertoire of beta-cell antigen-specific T cells and the variety of T cell subsets involved in type 1 diabetes development in human. RECENT FINDINGS: T cells that infiltrate islets of people with type 1 diabetes (i) react towards known islet cell antigens but also unknown antigens, (ii) differ from one patient to another, and (iii) are also present in the circulation, but not in the islets, of healthy people. Moreover, several circulating memory T cell subsets not recognized as relevant in mouse are significantly associated with clinical outcome. A more detailed understanding of the specificity, phenotype, and function of T cells that are associated with defined clinical outcomes might identify new pathways for therapeutic intervention.
PURPOSE OF REVIEW: Therapies that target beta-cell antigen-specific T cells subsets have not been as successful in patients with type 1 diabetes as in mice. This might be explained by complexities in the repertoire of beta-cell antigen-specific T cells and the variety of T cell subsets involved in type 1 diabetes development in human. RECENT FINDINGS: T cells that infiltrate islets of people with type 1 diabetes (i) react towards known islet cell antigens but also unknown antigens, (ii) differ from one patient to another, and (iii) are also present in the circulation, but not in the islets, of healthy people. Moreover, several circulating memory T cell subsets not recognized as relevant in mouse are significantly associated with clinical outcome. A more detailed understanding of the specificity, phenotype, and function of T cells that are associated with defined clinical outcomes might identify new pathways for therapeutic intervention.
Authors: Susanne J Szabo; Brandon M Sullivan; Claudia Stemmann; Abhay R Satoskar; Barry P Sleckman; Laurie H Glimcher Journal: Science Date: 2002-01-11 Impact factor: 47.728
Authors: M Radenkovic; K Uvebrant; O Skog; L Sarmiento; J Avartsson; P Storm; P Vickman; P-A Bertilsson; M Fex; O Korgsgren; C M Cilio Journal: Clin Exp Immunol Date: 2016-12-12 Impact factor: 4.330
Authors: John W McGinty; I-Ting Chow; Carla Greenbaum; Jared Odegard; William W Kwok; Eddie A James Journal: Diabetes Date: 2014-04-04 Impact factor: 9.461
Authors: Martha Campbell-Thompson; Ann Fu; John S Kaddis; Clive Wasserfall; Desmond A Schatz; Alberto Pugliese; Mark A Atkinson Journal: Diabetes Date: 2015-11-18 Impact factor: 9.461
Authors: Mateusz Gliwiński; Dorota Iwaszkiewicz-Grześ; Anna Wołoszyn-Durkiewicz; Monika Tarnowska; Magdalena Żalińska; Matylda Hennig; Hanna Zielińska; Anna Dukat-Mazurek; Joanna Zielkowska-Dębska; Maciej Zieliński; Anna Jaźwińska-Curyłło; Radosław Owczuk; Przemysława Jarosz-Chobot; Artur Bossowski; Agnieszka Szadkowska; Wojciech Młynarski; Natalia Marek-Trzonkowska; Grażyna Moszkowska; Janusz Siebert; Małgorzata Myśliwiec; Piotr Trzonkowski Journal: BMJ Open Diabetes Res Care Date: 2020-02
Authors: Jennie H M Yang; Leena Khatri; Marius Mickunas; Evangelia Williams; Danijela Tatovic; Mohammad Alhadj Ali; Philippa Young; Penelope Moyle; Vishal Sahni; Ryan Wang; Rejbinder Kaur; Gillian M Tannahill; Andrew R Beaton; Danielle M Gerlag; Caroline O S Savage; Antonella Napolitano Rosen; Frank Waldron-Lynch; Colin M Dayan; Timothy I M Tree Journal: Front Immunol Date: 2019-10-31 Impact factor: 7.561